Mark A. Beck
Known title: DirectorCIK: 0001603310
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IDEX price target raised to $285 by RBC Capital. RBC Capital has kept its outperform rating on IDEX and lifted the target price to $285, reflecting confidence in the company's earnings outlook. The move comes as the stock trades near the upper end of its 52‑week range and shows a moderately strong RSI of 63.3. Analysts see the firm’s valuation as still attractive compared to peers. The update may influence how investors view IDEX’s growth prospects.
Transaction History
| ACH | ▲ Buy | Grant | 31,191 | $0 | 5/14/2026 | View on chart |
| IEX | ▲ Buy | Grant | 805 | $0 | 5/6/2026 | View on chart |
| ACH | ▲ Buy | Grant | 28,914 | $0 | 5/15/2025 | View on chart |
| IEX | ▲ Buy | Grant | 895 | $0 | 5/8/2025 | View on chart |
| ACH | ▼ Sell | Open Market | 9,344 | $161K | 6/5/2024 | View on chart |
| ACH | ▲ Buy | Grant | 11,154 | $0 | 5/9/2024 | View on chart |
| IEX | ▲ Buy | Grant | 745 | $0 | 5/7/2024 | View on chart |
| IEX | ▲ Buy | Grant | 770 | $0 | 5/25/2023 | View on chart |
| ACH | ▲ Buy | Grant | 9,344 | $0 | 5/12/2023 | View on chart |
| IEX | ▲ Buy | Grant | 825 | $0 | 5/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.